BCL2 and acute myeloid leukemia: Guideline-Aligned Targeted Node Utilization: All small-molecule strategies align with ELN 2024 AML guidelines and phase II/III trial evidence (AGILE, QUANTUM-R), translating resistance-related targetable nodes (e.g., BCL-2, Menin, spliceosome) into clinical practice, advancing genotype-driven management of AML drug resistance.